The fight against poliomyelitis has received a major boost as the World Health Organization (WHO) has prequalified an additional novel oral polio vaccine (nOPV2) for international use. This step expands access to a key tool in controlling outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2), especially in under-immunized populations, and strengthens global efforts to eradicate polio.
Poliomyelitis, a highly contagious viral disease, primarily affects young children and can cause irreversible paralysis. While wild poliovirus has been largely eliminated worldwide, cVDPV2 outbreaks remain a persistent challenge.
What WHO Prequalification Means
WHO prequalification ensures that a vaccine meets rigorous international standards for quality, safety, and efficacy. For nOPV2, this designation:
- Allows procurement through UN agencies like UNICEF, enabling wider distribution in outbreak-affected countries.
- Provides assurance to national immunization programs, particularly in resource-limited settings.
- Strengthens global supply chains by validating additional manufacturers.
Expanding Global Supply
The newly prequalified vaccine is produced in India using bulk vaccine technology transferred from Indonesia. This diversification of manufacturing increases resilience and reliability of global vaccine stockpiles, ensuring faster deployment during outbreaks.
Why nOPV2 Matters
Unlike traditional monovalent oral polio vaccine type 2, nOPV2 is genetically engineered for greater stability. This innovation:
- Reduces the risk of vaccine-derived outbreaks
- Maintains the vaccine’s ability to quickly stop virus transmission
- Has been deployed in emergency responses, reaching hundreds of millions of children worldwide
WHO authorizes nOPV2 for emergency use across all age groups when required by its guidelines or the Global Polio Eradication Initiative.
Real-World Impact
WHO reports that vaccination campaigns, including the use of nOPV2, have contributed to declining wild polio cases worldwide. By increasing the pool of prequalified vaccines, countries can:
- Respond faster to outbreaks
- Protect vulnerable communities
- Strengthen the path toward a polio-free world
However, sustained surveillance, continued financing, and political commitment remain critical to fully eradicate polio.
FAQs
What is nOPV2?
nOPV2 is a novel oral polio vaccine engineered for increased genetic stability, designed to reduce the risk of vaccine-derived poliovirus type 2 outbreaks while effectively stopping virus transmission.
How does WHO prequalification help?
Prequalification confirms the vaccine meets international quality, safety, and efficacy standards, enabling UN agencies and countries to procure and distribute it globally.
Who manufactures the new nOPV2?
The newly prequalified vaccine is manufactured in India using technology transferred from Indonesia, adding to global production capacity.
Can nOPV2 be used in all age groups?
Yes, WHO authorizes nOPV2 for emergency use across all age groups during outbreak response efforts.
Why is nOPV2 important for eradication efforts?
Because it is genetically stable, nOPV2 minimizes the risk of vaccine-derived outbreaks, supports rapid interruption of virus transmission, and strengthens global strategies toward a polio-free world.
Conclusion
The WHO prequalification of an additional nOPV2 vaccine marks a critical milestone in the global campaign to eradicate polio. By expanding supply and enabling faster, safer deployment in outbreak-prone regions, nOPV2 strengthens international efforts to protect children and communities from this paralyzing disease.
While the progress is encouraging, sustained surveillance, funding, and political commitment are essential to ensure polio is completely eliminated worldwide.
